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LETTERS TO THE EDITOR
Formation of a
Bronchoesophageal
Fistula Following
Concurrent Radiation
and Chemotherapy for
Lung Cancer in the
Setting of Behc¸et’s
Disease
To the Editor:
A 53-year-old male smoker with
Behc¸et’s disease presented with chest
pain. Subsequent work-up revealed a 2.2
cm right lower lobe lung mass with right
hilar and mediastinal lymphadenopathy.
Bronchoscopy showed no endobronchial
lesions and no fistulas. Biopsy of a sub-
carinal mass demonstrated non-small cell
lung cancer.
His medical history was signifi-
cant for Behc¸et’s disease diagnosed in
his early 20’s. He developed the classic
triad of oral and genital ulcerations and
uveitis, which lead to blindness at age
28. He was initially treated with pred-
nisone and chlorambucil but had not
been on any immunosuppressive medi-
cations for the preceding 15 years. Oral
and genital ulcers would still develop
but would resolve spontaneously. At the
time of presentation he did not have
active areas of ulceration. His medical
history was otherwise unremarkable. On
review of systems he denied dysphagia
or odynophagia. He appeared thin but
healthy on physical examination, which
was otherwise unremarkable.
He was treated with definitive radi-
ation therapy (64 Gy) and chemotherapy
(cisplatin and etoposide), which he toler-
ated reasonably well. He developed acute
esophagitis and required both short and
long-acting narcotic analgesics and nutri-
tional supplements during the latter half of
his treatment.
Five weeks after completing treat-
ment he presented with fevers, cough, and
progressive odynophagia. Upper endoscopy
showed esophageal stenosis between 24 and
30 cm from the incisors with a possible
fistula at 27 cm. Subsequent bronchoscopy
confirmed a bronchoesophageal fistula be-
tween the esophagus and left mainstem
bronchus (Figure 1). A Y-silicone stent was
placed in the trachea and mainstem
bronchi to cover the fistula. An Alveolus
Alimaxx-E stent was then placed to tra-
verse the area of esophageal stenosis and
cover the esophageal portion of the fis-
tula. He improved clinically and was
discharged from the hospital. Unfortu-
nately, subsequent bronchoscopy showed
increasing size of the fistula. The patient’s
clinical status declined and he subse-
quently expired 5 months after completing
radiation therapy. Upon review of the ra-
diation fields, the fistula site was adjacent
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FIGURE 1. Bronchoscopic view of the fistula (white arrow). The bronchoscope is
in the left mainstem bronchus. A yellow Dobhoff tube in the adjacent esophagus is
seen through the fistulous connection.
FIGURE 2. Axial CT image of the region where the bronchoesophageal fistula devel-
oped (yellow contour), with the radiation isodose lines overlayed. The entire circumference
of the left mainstem bronchus and esophagus are encompassed by the 44 Gy isodose line
(blue contour). Portions of both structures received the full prescription dose (64 Gy) (red
contour). The subcarinal lymphadenopathy is just medial to the esophagus.
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to the subcarinal lymphadenopathy and
therefore received the full radiation dose
(Figure 2).
Most reports of unusual toxicities
after radiation therapy in patients with
collagen vascular diseases have been with
systemic lupus, rheumatoid arthritis, or
scleroderma.1 Behc¸et’s disease is a rare
condition characterized by the formation
of aphthous ulcers.2 Patients commonly
present with oral and genital ulcerations
but ulcers can develop in the gastrointes-
tinal tract, including the esophagus.2,3
Only one study has been published
reporting unusual toxicities in patients
with Behc¸et’s disease treated with radia-
tion therapy. Cengiz et al4 observed severe
late toxicity developing in 3 of 6 patients
treated with radiation therapy. A patient
with Hodgkin lymphoma developed bra-
chial plexopathy following 40 Gy to a
mantle field, a dose well below that ex-
pected to result in neurotoxicity. Another
patient developed ureteral stricture follow-
ing postoperative external beam radiation
therapy (50 Gy) for cervical cancer. Fi-
nally, a third patient developed skin necro-
sis after treatment of a malignant mesen-
chymal tumor (70 Gy).
Bronchoesophageal fistulas are rarely
seen in patients treated for lung cancer
with conventional doses of radiation ther-
apy. Oncologists treating patients with
Behc¸et’s disease should be aware of the
potential increased risk of normal tissue
toxicity and should consider screening for
esophageal ulcers before initiating treat-
ment for thoracic tumors.
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Synchronous Pulmonary
MALT Lymphoma and
Pulmonary
Adenocarcinoma after
Metachronous Gastric
MALT Lymphoma and
Gastric Adenocarcinoma
To the Editor:
A 74-year-old man presented with
a cough and bloody sputum in 2005. He
had been treated curatively with radia-
tion for gastric mucosa associated lym-
phoid tissue (MALT) lymphoma in
2003 and had undergone endoscopic re-
section of an early gastric adenocarci-
noma in 2004. Computed tomography
revealed an ill-defined mass and two
small nodules with ground-glass opacity
in the left apicoposterior segment (Fig-
ure 1A). The mass was diagnosed as ad-
enocarcinoma on transbronchial biopsy
and a left upper lobectomy was per-
formed. Papillary adenocarcinoma was
confirmed (Figure 1B) and the mass was
considered a primary lung cancer because
of positive immunohistochemical staining
for surfactant protein A. The remaining
two lesions were diagnosed as MALT lym-
phoma (Figure 1C). Helicobacter pylori was
not found in either the pulmonary or gastric
MALT lymphoma. The polymerase chain
reaction analysis suggested that the lym-
phomas of both the lung and stomach
developed through a common mechanism,
API2-MALT1 (data not shown).
MALT lymphoma is caused by Hel-
icobacter pylori, autoimmune disease, and
genomic alternations such as the API2-
MALT1 gene.1 The synchronous occur-
rence of MALT lymphoma and adenocarci-
noma has often been documented in the
stomach and Helicobacter pylori seems to
be one of the common causes of both dis-
eases.2 To our knowledge, eight cases in-
cluding the present one, with simultaneous
lung cancer and pulmonary MALT lym-
phoma have been reported.3,4 The histology
of lung cancer was adenocarcinoma in seven
of the eight cases and MALT lymphoma
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FIGURE 1. (A) Chest computed tomography showing an ill-defined mass (arrow)
in the left apicoposterior segment and two nodules (arrowheads) adjacent to the
mass. (B) Hematoxylin-eosin staining of the papillary adenocarcinoma specimen.
The lesion is shown by the arrows in A. (C) Hematoxylin-eosin staining of the
MALT lymphoma. The lesion is shown by the arrowheads in A.
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